

RSC Medicinal Chemistry

rsc.li/medchem



ISSN 2632-8682

RESEARCH ARTICLE

Ioannis P. Papanastasiou *et al.*
New *Trypanosoma brucei* acting derivatives
incorporating 1-(4-phenyl)adamantane and
1-(4-phenoxyphenyl)adamantane

RESEARCH ARTICLE

View Article Online
View Journal | View IssueCite this: *RSC Med. Chem.*, 2025, 16,
2441New *Trypanosoma brucei* acting derivatives
incorporating 1-(4-phenyl)adamantane and 1-(4-
phenoxyphenyl)adamantane†Konstantina Stavropoulou,^{‡a} Angeliki Kaimaki,^{‡a} Maria Nikolaou,^{‡a}
Ana K. Brown,^{‡ab} Andrew Tsotinis,^{‡a} Martin C. Taylor,^{‡c}
John M. Kelly,^{‡c} and Ioannis P. Papanastasiou^{‡*a}

In this work, we describe the design, synthesis and evaluation of novel functionalised 1-(4-phenyl)adamantane and 1-(4-phenoxyphenyl)adamantane derivatives. Based on previous findings, we incorporated a phenyl ring between the adamantane core and the pharmacophoric side chain to enhance the activity and selectivity index (SI). The aromatic imidazolines **1a-d** and the linear amidines **2a,b** and **3a,b** exhibited notable activity against *T. brucei*. The 1-(4-phenyl)adamantane 1-(4-phenoxyphenyl)adamantane core was further functionalized with the aminoguanylhydrazone and thiosemicarbazone moieties. 2-[(*E*)-4-(1-adamanty)benzylidene]hydrazine-1-carbothioamide **4c** emerged as a promising trypanocidal agent with an EC₅₀ of 0.16 μ M and an SI of 17. Future studies will focus on optimizing the length and the distance of the side chain between the aromatic ring and the chromophores to further enhance the activity and selectivity of these molecules.

Received 11th February 2025,
Accepted 22nd April 2025

DOI: 10.1039/d5md00135h

rsc.li/medchem

Introduction

Human African Trypanosomiasis (HAT) is a neglected tropical disease endemic to sub-Saharan Africa. Although detected cases have recently dropped below 1000 annually,¹ the risk of large epidemic outbreaks remains high, and trypanosome infections continue to impose a large disease burden on domestic livestock throughout the region. The treatment of late-stage HAT (when parasites have accessed the CNS) with nifurtimox–eflornithine combination therapy (NECT) requires systematic hospitalization, which poses challenges in resource-limited areas. The recent introduction of fexinidazole as an oral drug has therefore been an important advance.² However, further chemotherapeutic options are needed to maintain progress towards elimination of the disease as a public health problem, and there remains a demand for new veterinary drugs.

Pentamidine is a diamidine that has been used in the treatment of stage 1 (hemolymphatic) gambiense HAT for

nearly 80 years. Several mechanisms have been suggested for pentamidine activity, but the precise mode of action and its main targets have not been entirely elucidated. Pentamidine is believed to be a DNA minor groove binder, particularly to AT-rich regions. However, antimicrobial activity of pentamidine does not correlate well with the DNA binding action.^{3,4} In addition, pentamidine interrupts tRNA aminoacylation, by the entropy-driven non-specific binding, which inhibits translation.⁵ The drug has also been shown to inhibit enzymes such as topoisomerases of both *Pneumocystis carinii* and African trypanosomes,^{6,7} the phosphatase of regenerating liver,⁸ and to selectively modify ubiquitin.⁹ Resistance to pentamidine is associated with an inability of the diamidine to reach its target(s). The aquaglyceroporin TbAQP2 has been demonstrated to be the major mediator of pentamidine uptake,^{10–12} and to correspond to the previously identified high-affinity pentamidine transporter (HAPT 1).



Fig. 1 Pentamidine, furamidines and other amidine derivatives.

^a Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 157 71 Athens, Greece. E-mail: papanastasiou@pharm.uoa.gr^b Department of Chemistry, University of San Francisco, 2130 Fulton Street, San Francisco, California, CA 94117, USA^c Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1 E7HT, UK† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d5md00135h>

‡ Equal contribution as co-first authors.

Other transporters also contribute to a lesser extent, including TbAT1, LAPT1 (ref. 13) and P-glycoprotein (P-gp)-like and organic cation transporters (OCT).¹⁴ The trypanosome P2 transporter (TbAT1) is substantially different from the analogous human mammalian nucleoside transporters.¹⁵ However, the P2 transporter has a recognition motif, which is common between the amino-purines, the melamine-based arsenicals and the diamidines, and consists of an amidine moiety, an aromatic ring and an electronegative heteroatom.¹⁶

In this study, we present the synthesis of new aromatic amidines, building on our previous findings and exploring the chemical space of adamantane derivatives and their biological potential against trypanosomes. In our earlier work, we synthesized spiro **I** and non-spiro **II** and **III** imidazoline derivatives, each incorporating an amidine moiety within the scaffold, along with the lipophilic adamantane core (Fig. 1).^{17,18} We have also observed that inserting a phenyl ring between the adamantane core and the functional side chain improved, in certain cases, the activity and selectivity.¹⁹ Bis(arylimidamides) are known to target kinetoplastid parasites.²⁰ In the present work, we modified the imidazoline scaffold to include the aromatic imidazolines **1a–d** and the exocyclic aromatic amidines **2a,b**. Additionally, we introduced a benzylphenylether spacer, previously employed in related studies,²¹ into the **3a** amidine.

Imines and their congeneric classes of compounds, such as Schiff bases, thio/semicarbazones, hydrazones, and benzopyrazines, are endowed with biological activity, which has been exploited in drug development. Therefore, the side chains of the new derivatives were further functionalized with aminoguanylhydrazone and thiosemicarbazone groups, affording the derivatives **4a–c**, **5a–c** and **6a–c**. These two pharmacophores are well-known for their trypanocidal activity,^{22–25} among other properties.^{26–29} In particular, aromatic adamantane secondary thiosemicarbazones exhibit antimicrobial activity.³⁰ Moreover, the incorporation of a halogen atom onto the aromatic ring may enhance biological activity or reduce toxicity, as observed in similar aminoguanylhydrazones.³¹ This approach was applied to derivatives **5a–c** and **6a–c** (Fig. 2).

Results and discussion

Chemistry

The preparation of the 4-phenyl-2-imidazolines **1a–d** was realized by the reaction sequence illustrated in Scheme 1.

For the preparation of the 4-phenyl-2-imidazolines **1a–d**, the key compound 4-(1-adamantyl)benzaldehyde (**9**)³² was converted to the α -aminoacetonitrile **10** via the Strecker reaction.^{33,34} The latter was hydrogenated to the corresponding diamine **11**, which upon treatment with the requisite formamidine acetate, acetamidine hydrochloride or cyanogen bromide afforded the imidazolines **1a–c**, respectively.¹⁷ The benzaldehyde **9** was converted to the 2-imidazoline **1d** upon treatment with



Fig. 2 New 1-(4-phenyl)adamantane, 1-(4-phenoxyphenyl)adamantane and 1-(4-benzoyloxyphenyl)adamantane functionalized derivatives with trypanocidal activity.

iodine, ethylenediamine and potassium carbonate.³⁵ In this work, we also report the smooth reduction of the Weinreb amide **8** by lithium diisobutyl-*tert*-butoxyaluminum hydride (LDBBA)³⁶ to the respective benzaldehyde **9** and two different ways for the Weinreb amide **8**³⁷ preparation. One route, involved the activation of the benzoic acid **7**³⁸ by the Deoxo-Fluor reagent and then treatment with *N,O*-dimethylhydroxylamine.^{39,40} In the second preparation, the benzoic acid **7** was transformed to the intermediate alkyloxyphosphonium salt, *via* an Appel type reaction with



Scheme 1 Reagents and conditions: (a) $\text{N}(\text{CH}_2\text{CH}_2\text{OMe})_2\text{SF}_3$, DIPEA, DCM, 0 °C, 30 min; (b) $\text{HN}(\text{OMe})\text{Me}\cdot\text{HCl}$, DIPEA, DCM, 0 °C, 30 min, rt for 24 h, 55 °C for 24 h; (c) PPh_3 , NBS, 0 °C, 15 min; (d) $\text{HN}(\text{OMe})\text{Me}\cdot\text{HCl}$, Et_3N , DCM, rt, 3 h; (e) LDBBA, THF, 0 °C, 30 min; (f) NaCN , $\text{CH}_3\text{NH}_2\cdot\text{HCl}$, $\text{DMSO}:\text{H}_2\text{O}$, 9:1, 60 °C, 7 h; (g) H_2/PtO_2 , EtOH, $\text{HCl}(\text{g})/\text{EtOH}$, 55 psi, rt, 4.5 h; (h) formamidine acetate or acetamidine hydrochloride, EtOH, reflux, 48 h; (i) BrCN , DCM, rt, 48 h; (j) I_2 , ethylenediamine, K_2CO_3 , *tert*-BuOH, 70 °C, 3 h.



NBS and TPP, which was then treated with *N,O*-dimethylhydroxylamine.⁴¹

The linear aromatic adamantane amidines **2a,b** and **3a,b** were prepared as shown in Scheme 2. We adopted a facile and efficacious method for the synthesis of amidines **2a** and **3a,b** from the corresponding nitriles **12**,⁴² **14**, **16** and **19** via the reduction of the intermediate amidoximes, in the presence of $\text{Ac}_2\text{O}/\text{AcOH}/\text{Zn}$ at room temperature.⁴³ Acetamidine **2b** was afforded directly from the phenoacetonitrile **14** (ref. 32) upon treatment with the aluminum amide, reagent generated *in situ*.⁴⁴ The 4-phenoxyphenylnitrile **15** and the 4-benzyloxyphenylnitrile **19** were afforded by a nucleophilic aromatic substitution of the requisite alcohols **15** (ref. 32) and **18** (ref. 32) to the 4-fluorobenzonitrile.

The synthesis of the aminoguanylhydrazones and thiosemicarbazones **4a–c**, **5a–c** and **6a–c** is depicted in Scheme 3. The parent benzaldehydes **9**, **21–23** were coupled with aminoguanidine bicarbonate, semicarbazide hydrochloride and thiosemicarbazide, respectively, leading to the corresponding final derivatives **4a–c**, **5a–c** and **6a–c**. The 4-phenoxybenzaldehydes **21–23** were prepared from the phenol **15** in a similar way²⁶ to the aforementioned 4-phenoxyphenylnitrile **16**.

Pharmacology

The new adamantane adducts were tested for their activity against the bloodstream-form *Trypanosoma brucei* and the results are listed in Table 1.

It is apparent from the test results that the 2-imidazolines **1a–d** are less cytotoxic than their linear congeners **2a,b** and **3a**, **b**, although the latter are generally more potent. The insertion of the phenyl ring between the adamantane core and the side chain confirmed the improvement of the antiparasitic potency of the 5-phenyl-2-imidazolines *versus* their congeners, with a phenyl substitution at C3 of adamantane or N1 of

imidazolines.³⁴ Additionally, the linker connecting the two aromatic rings appears to affect the pharmacological profile of these compounds. A two-atom distance (C, O) between the two aromatic rings lowers the activity as is evident by comparing the 4-benzyloxyphenyl amidine **3b** and the 4-phenoxyphenyl amidine **3a**. A bioisosteric replacement of the oxygen atom between the two rings is a promising avenue for future development of these derivatives.

The relative distance between the phenyl ring and the functional group at the side chain has an impact on both the activity and cytotoxicity. Notably, the acetamidine **2b** is more potent than benzamidine **2a** and the diaryl amidine **3a** presents even higher activity. These results prompted us to further explore the impact of the length and the distance of the side chain between the aromatic ring and the functional group. Amongst the aminoguanylhydrazones and thiosemicarbazones **4a–c**, **5a–c** and **6a–c**, the monoaryl adducts were better tolerated. The thiosemicarbazone **4c** exhibited the most promising pharmacological profile among these series of derivatives with a higher SI. This derivative has been also identified as antimycobacterial in a whole cell high-throughput screen.⁴⁵ In contrast, the semicarbazone moiety (adduct **4b**) has no trypanocidal effect. The impact of chlorine substitution on activity remains unclear in these derivatives, even though the non-substituted thiosemicarbazone **6a** is less potent than its chlorinated congeners **6b** and **c**. Additionally, the aromatic adamantane aminoguanylhydrazones and thiosemicarbazones reported here are more potent than the previously described non-aromatic adamantane.^{46,47}


Conclusions

The results of the current study confirm that the insertion of a phenyl ring between the adamantane core and the side chain improves the pharmacological profile of 5-phenyl-2-imidazolines compared to those with phenyl substitutions at



Scheme 2 Reagents and conditions: (a) i. $\text{NH}_2\text{OH}\cdot\text{HCl}$, DIPEA, EtOH, rt, 1 h; ii. EtOH, reflux, 16 h; (b) i. Ac_2O , AcOH, rt, 1.5 h; ii. Zn, rt, 24 h; iii. NaOH 5 M; (c) i. NH_4Cl , $\text{Al}(\text{Me})_3$, toluene dry, 2 h, 0 °C to rt; 80 °C, 19 h; iii. SiO_2 , DCM, rt, 10 min; (d) i. NaH, DMF dry, rt, 10 min; ii. 4-fluorobenzonitrile, DMF dry, 100 °C, 24 h.





Scheme 3 Reagents and conditions: (a) aminoguanidine bicarbonate, EtOH, conc. HCl drops, 18 h; (b) semicarbazide hydrochloride, EtOH, HCl drops, 18 h; (c) thiosemicarbazide, EtOH, conc. HCl drops, 18 h; (d) K_2CO_3 , DMF dry, 2-chloro-4-fluorobenzaldehyde, 160 °C, 24 h; (e) K_2CO_3 , DMF dry, 4-fluorobenzaldehyde, 160 °C, 24 h; (f) K_2CO_3 , DMF dry, 3-chloro-4-fluorobenzaldehyde, 160 °C, 24 h.

Table 1 Activity and cytotoxicity of the new derivatives

Cmpd	<i>T. brucei</i> EC ₅₀ ^a (μM)	<i>T. brucei</i> EC ₉₀ ^a (μM)	HeLa cells EC ₅₀ (μM)	SI ^b
1a	0.93 ± 0.05	1.42 ± 0.15	3.68 ± 0.12 ^c	4.3
1b	1.39 ± 0.03	1.69 ± 0.02	5.59 ± 0.94 ^c	4.0
1c	1.58 ± 0.05	2.11 ± 0.16	7.58 ± 0.64 ^c	4.8
1d	1.54 ± 0.05	2.07 ± 0.08	3.06 ± 0.34 ^c	2.0
2a	1.15 ± 0.19	1.90 ± 0.37	1.55 ± 0.13	1.3
2b	0.67 ± 0.02	0.86 ± 0.02	2.04 ± 0.18	3.0
3a	0.27 ± 0.01	0.34 ± 0.01	0.82 ± 0.10	3.0
3b	0.69 ± 0.02	0.99 ± 0.20	0.93 ± 0.06	1.3
4a	0.36 ± 0.03	0.44 ± 0.03	1.17 ± 0.09	3.3
4b	>100	>100	>100	—
4c	0.16 ± 0.02	0.27 ± 0.01	2.77 ± 0.14	17
5a	0.34 ± 0.01	0.45 ± 0.01	0.54 ± 0.01	1.6
5b	0.70 ± 0.10	1.02 ± 0.02	<0.22	<1
5c	0.33 ± 0.03	0.51 ± 0.01	<0.22	<1
6a	>35	>35	—	—
6b	0.45 ± 0.03	0.88 ± 0.04	0.26 ± 0.04	<1
6c	1.39 ± 0.09	2.44 ± 0.32	2.08 ± 0.21	1.5
Pent	0.0019 ± 0.0001	0.0044 ± 0.0001	5.70 ± 0.61	3000

^a EC₅₀/EC₉₀; concentrations that inhibit growth by 50% and 90%. ^b S.I.; selectivity index, the ratio of EC₅₀ values obtained with HeLa cells and *T. brucei*. ^c Cytotoxicity was established using L6 cells in these cases; Pent, pentamidine.

C3 or N1. The linker between the two aromatic rings also affects activity, with a two-atom (C, O) distance reducing potency and increasing cytotoxicity. Future studies could explore bioisosteric modifications replacing the oxygen atom. Among the aminoguanidylhydrazone and thiosemicarbazone functionalised derivatives, thiosemicarbazone **4c** has shown the most promising pharmacological profile. Additionally, the distance between the phenyl ring and the functional group in the side chain affects both activity and cytotoxicity. These results suggest that further investigation into optimizing the side chain length and the relative position of the structural features is warranted.

Biology

Cytotoxic activity against mammalian cells. Cytotoxicity against mammalian cells (HeLa or L6, a rat skeletal myoblast line) was assessed using microtitre plates. Briefly, cells were seeded at 1×10^4 mL⁻¹ in 200 μL of growth medium containing 7 different compound concentrations in a range previously established to encompass both the EC₅₀ and EC₉₀ values. The plates were incubated for 6 days at 37 °C and 20 μL resazurin (at 0.125 mg mL⁻¹) was then added to each well.

§ HeLa and L6 cells were obtained from the London School of Hygiene and Tropical Medicine (LSHTM) cell line repository.



After an additional 8 hours incubation, the fluorescence was determined using a FLUOstar Omega fluorescent plate reader (BMG Labtech). Inhibition of growth was calculated by comparison with control values and EC₅₀ and EC₉₀ values were determined in triplicate using linear regression analysis.

Trypanosoma brucei culturing and drug testing.

Bloodstream form *T. brucei* (strain 427) were cultured at 37 °C in modified Iscove's medium. Trypanocidal activity was assessed by growing parasites in microtiter plates in the presence of various drug concentrations. Parasites were seeded at $0.25 \times 10^5 \text{ mL}^{-1}$ in 200 μL of growth medium containing 7 different compound concentrations in a range previously established to encompass both the EC₅₀ and EC₉₀ values. The plates were incubated for 48 hours at 37 °C and 20 μL resazurin (as above) was then added to each well. After an additional overnight incubation, the fluorescence was determined using a FLUOstar Omega fluorescent plate reader, and growth inhibition calculated. Values were determined in triplicate using linear regression analysis.

Synthetic procedures. All chemicals and solvents were obtained from commercial suppliers and used without further purification. Reactions were monitored by thin layer chromatography. Melting points were determined on a Sanyo Gallenkamp apparatus and are uncorrected. Infrared (IR) spectra were recorded on a Perkin-Elmer 833 spectrophotometer. ¹H-NMR spectra recorded on a Bruker DRX 400 (400 MHz) spectrometer and ¹³C-NMR spectra were taken at 50 MHz on Bruker AC 200 (200 MHz) spectrometer and at 150 MHz on Bruker Avance 600 spectrometer (600 MHz). All NMR spectra were taken in deuterochloroform or hexadeuterodimethyl sulfoxide and the chemical shifts are reported in ppm. Elemental analyses (C, H, N) were carried out by the Institute of Chemical Biology, NHRF, Greece and the results obtained had a maximum deviation of $\pm 0.4\%$ from the theoretical value.

4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)benzaldehyde (9).³² To a stirring solution of Weinreb amide **8** (750 mg, 2.5 mmol) in THF (15 mL) under argon at 0 °C, LDBBA³⁶ (17.1 mL, 0.44 M, 7.5 mmol) was added dropwise and the reaction mixture was stirred at 0 °C for 2 h. The reaction was quenched with an aqueous solution of sodium bicarbonate. The two phases were separated and the aqueous layer was extracted with EtOAc. The combined organic layers are dried over Na₂SO₄ and concentrated under vacuum to afford **9**. The product was used without further purification to the next reaction.

4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)-N-methoxy-N-methylbenzamide (8)³⁷

A method. To a stirring solution of 4-(1-adamantyl) benzoic acid (**7**) (500 mg, 1.95 mmol) in dichloromethane (10 mL) under argon, at 0 °C, DIPEA (mmol 0.5 mL, 2.93 mmol) and Deoxo-Fluor (0.9 mL, 2.7 M, 2.34 mmol) was added. The reaction mixture was stirred at the same temperature for 30 min. To a solution of *N,O*-dimethylhydroxylamine hydrochloride (286 mg, 2.93 mmol) in dichloromethane (5 mL), DIPEA (0.5 mL) was added under cooling (~ 0 °C) and the reaction mixture is stirred for 5 min. The prepared

solution of *N,O*-dimethylhydroxylamine was added to the acyl fluoride mixture and stirred at 0 °C for 30 min, and then was heated to 55 °C for 24 h. An aqueous solution of NaHCO₃ was added to the reaction mixture and the aqueous layer was extracted with dichloromethane. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by gradient flash column chromatography. Elution with a mixture of EtOAc:*n*-hexane:acetic acid, 1:10:0.01 to 3:7:0.01 afforded 303 mg of **8**. Yield 52%.

B method. To a stirring solution of 4-(1-adamantyl) benzoic acid (**7**) (600 mg, 2.34 mmol) and PPh₃ (920 mg, 3.51 mmol) in anhydrous dichloromethane (20 mL) at 0 °C, NBS (625 mg, 3.51 mmol) was added and the reaction mixture was stirred under cooling for 45 min. Then, the reaction mixture was stirred at rt and *N,O*-dimethylhydroxylamine hydrochloride (342 mg, 8.23 mmol) and triethylamine (0.35 mL, 2.54 mmol) were added and the resulting mixture was stirred at rt for 24 h. The reaction was quenched with an aqueous solution of sodium bicarbonate. The two phases were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography with an eluent mixture of 10% EtOAc in dichloromethane to afford 450 mg of **8**. Yield 64%. M.p.: 123–124 °C.

α -Methylamino-[4-(1-tricyclo[3.3.1.1^{3,7}]decyl)phenyl] acetone nitrile hydrochloride (10). To a stirring suspension of sodium cyanide (588 mg 12, mmol) and methylamine hydrochloride (810 mg, 12 mmol) in a mixture of DMSO:H₂O, 9:1 (5 mL), a solution of carboxaldehyde **9** (1.44 g, 6 mmol) in DMSO (10 mL) was added and the reaction mixture was stirred under argon atmosphere at rt for 48 h and then was heated at 60 °C for 7 h. The reaction was quenched with an aqueous solution of sodium bicarbonate. The two phases were separated and the aqueous layer was extracted with diethyl ether. The combined organic layers were washed with water, dried over Na₂SO₄ and concentrated under vacuum. The residue was transformed into hydrochloride. 1.35 g, yield 80%. M.p.: 238–241 °C (ethanol-diethyl ether); ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 10.95 (br. s, 2H, NH₂), 7.66–7.68 (d, 2H, *J* = 8.4 Hz, 2,6-Har), 7.51–7.53 (d, 2H, *J* = 8.4 Hz, 3,5-Har), 6.01 (s, 1H, α -H), 2.58 (s, 3H, CH₃), 2.06 (br. s, 3H, 3,5,7-Had), 1.86–1.87 (m, 6H, 2,8,9-Had), 1.70–1.76 (m, 6H, 4,6,10-Had). ¹³C-NMR (101 MHz, DMSO-*d*₆) δ (ppm): 170.7 (1-Car), 153.6 (4-Car), 129.2 (2,6-Car), 125.7 (3,5-Car), 115.2 (CN), 50.7 (α -C), 42.3 (2,8,9-Cad), 41.9 (1-Cad), 36.0 (4,6,10-Cad), 30.9 (CH₃), 28.2 (3,5,7-Cad).

***N'*-Methyl-1-[4-(1-tricyclo[3.3.1.1^{3,7}]decyl)phenyl]-1,2-ethane diamine dihydrochloride (11).** To a stirring solution of nitrile hydrochloride **10** (1.1 g 3.9 mmol) in ethanol (50 mL) and saturated ethanolic hydrogen solution (5 mL), Adam's catalyst platinum oxide (150 mg) was added into the reaction mixture, which then was hydrogenated under 55 psi for 4.5 h. The catalyst is then filtered off and the filtrate was concentrated under vacuum to afford the diamine



dihydrochloride 1.1 g of **11**. Almost quantitative yield. M.p.: >250 °C (methanol-ether); $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 10.44 (br. s, 1H, NH), 9.99 (br. s, 1H, NH), 8.54 (br. s, 3H, NH_3), 7.59–7.61 (d, 2H, $J = 8.4$ Hz, 2,6-Har), 7.46–7.48 (d, 2H, $J = 8.4$ Hz, 3,5-Har), 4.49–4.52 (m, 1H, α -H), 3.62–3.67 (m, 1H, β -H), 3.34–3.39 (m, 1H, β -H), 2.32 (s, 3H, CH_3), 2.06 (s, 3H, 3,5,7-Had), 1.87 (s, 6H, 2,8,9-Had), 1.73–1.74 (m, 6H, 4,6,10-Had). $^{13}\text{C-NMR}$ (101 MHz, $\text{DMSO-}d_6$) δ (ppm): 152.4 (1,4-Car), 128.9 (2,6-Car), 125.5 (3,5-Car), 59.4 (α -C), 42.4 (2,8,9-C), 40.5 (β -C), 36.1 (4,6,10-Cad), 35.8 (1-Cad), 30.2 (CH_3), 28.3 (3,5,7-Cad).

4,5-Dihydro-1-methyl-5-[4-(1-tricyclo[3.3.1.1^{3,7}]decyl)phenyl]-1H-imidazole (1a). Diamine dihydrochloride **11** (370 mg, 1.3 mmol) was dissolved in absolute ethanol (10 mL) and formamidine acetate (177 mg, 1.7 mmol) is added and the reaction mixture was stirred at rt under argon atmosphere for 24 h and then was heated to 50 °C for 24 h. Then, the solvent was removed under vacuum and the residue was treated with solution HCl 4% (30 mL) and the resulting mixture was washed with EtOAc. The aqueous layer was basified with a solution of NaOH 4% and then extracted with EtOAc. The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated under vacuum to afford 227 mg of **1a**, yield: 77%. The product was transformed into fumarate. M.p.: 202–204 °C (methanol-ether); $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 8.10 (br. s, 1H, 2-Him), 7.40–7.43 (d, 2H, $J = 8.2$ Hz, 2,6-Har), 7.29–7.31 (d, 2H, $J = 8.2$ Hz, 3,5-Har), 6.48 (s, 2H, $\text{CH}_2=$, fumarate), 4.85–4.90 (m, 1H, 5-Him), 4.22–4.28 (m, 1H, 4-Him), 3.57–3.63 (m, 1H, 4-Him), 2.78 (s, 3H, CH_3), 2.05 (s, 3H, 3,5,7-Had), 1.85 (s, 6H, 2,8,9-Had), 1.73–1.74 (m, 6H, 4,6,10-Had). $^{13}\text{C-NMR}$ (101 MHz, $\text{DMSO-}d_6$) δ (ppm): 167.8 (C=O), 158.1 (2-Cim), 151.2 (1,4-Car), 135.1 (CH= , fumarate), 127.0 (2,6-Car), 125.4 (3,5-Car), 64.9 (5-Cim), 57.0 (4-Cim), 42.5 (2,8,9-Cad), 36.1 (4,6,10-Cad), 35.7 (1-Cad), 32.2 (CH_3), 28.27 (3,5,7-Cad). Anal. calc. for $\text{C}_{24}\text{H}_{30}\text{N}_2\text{O}_4$ (%): C, 70.22; H, 7.37; N, 6.82, found: (%) C, 70.46; H, 7.01; N, 6.58.

4,5-Dihydro-1,2-dimethyl-5-[4-(1-tricyclo[3.3.1.1^{3,7}]decyl)phenyl]-1H-imidazole (1b). To a solution of diamine dihydrochloride **11** (370 mg, 1.3 mmol) in absolute ethanol (10 mL) acetamidine hydrochloride (161 mg, 1.7 mmol) was added and the reaction mixture was stirred at rt under argon atmosphere for 24 h and then was heated to 50 °C for 24 h. Then, the solvent was removed under vacuum and the residue was treated with a solution of HCl (30 mL, 4%). The resulting mixture was washed with EtOAc and the aqueous layer was basified with solution NaOH 4% and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated under vacuum to afford 201 mg of **1b**, yield: 65%. The product was transformed into fumarate. M.p.: 182–184 °C (ethanol-diethyl ether); $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ (ppm): $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 7.42–7.44 (d, 2H, $J = 8.4$ Hz, 3,5-Har), 7.32–7.34 (d, 2H, $J = 8.4$ Hz, 2,6-Har), 6.45 (s, 2H, CH= , fumarate), 5.03–5.09 (m, 1H, 5-Him), 4.15–4.21 (m, 1H, 4-Him), 3.53–3.59 (m, 1H, 4-Him), 2.75 (s, 3H, 1- CH_3), 2.32 (s, 3H, 2- CH_3), 2.05 (s, 3H, 3,5,7-

Had), 1.86 (s, 6H, 2,8,9-Had), 1.73–1.74 (m, 6H, 4,6,10-Had). $^{13}\text{C-NMR}$ (101 MHz, $\text{DMSO-}d_6$) δ (ppm): 168.1 (C=O), 166.9 (2-Cim), 151.7 (1,4-Car), 135.3 (CH= , fumarate), 127.2 (2,6-Car), 125.5 (3,5-Car), 65.6 (5-Cim), 52.1 (4-Cim), 42.5 (2,8,9-C), 36.1 (4,6,10-Cad), 35.7 (1-Cad), 30.8 (1- CH_3), 28.3 (3,5,7-Cad), 11.9 (2- CH_3). Anal. calc. for $\text{C}_{25}\text{H}_{32}\text{N}_2\text{O}_4$ (%): C, 70.73; H, 7.60; N, 6.60; found: (%) C, 70.26; H, 7.77; N, 6.39.

4,5-Dihydro-1-methyl-5-[4-(1-tricyclo[3.3.1.1^{3,7}]decyl)phenyl]-1H-2-imidazolamine (1c). To a stirring solution of diamine **11** (825 mg, 2.9 mmol) in anhydrous dichloromethane (10 mL) at 0 °C, a solution of cyanogen bromide (384 mg, 3.6 mmol) in anhydrous dichloromethane (5 mL) was added dropwise and the reaction mixture was stirred at rt, under argon atmosphere for 48 h. Then, the reaction mixture was concentrated under vacuum and the residue was treated with anhydrous diethyl ether and the hydrobromide crystallized to afford 258 mg of **1c**. Yield of hydrobromide: 66%. M.p.: 253–255 °C (dec). (ethanol-diethyl ether); $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ (ppm): 8.15 (s, 1H, 3-Him), 7.99 (s, 1H, 2-Him), 7.41–7.43 (d, 2H, $J = 8.2$ Hz, 2,6-Har), 7.28–7.30 (d, 2H, $J = 8.2$ Hz, 3,5-Har), 4.86–4.91 (m, 1H, 5-Him), 3.92–3.97 (m, 1H, 4-Him), 3.30–3.38 (m, 1H, 4-Him), 2.68 (s, 3H, CH_3), 2.04 (s, 3H, 3,5,7-Had), 1.85 (s, 6H, 2,8,9-Had), 1.72 (m, 6H, 4,6,10-Had). $^{13}\text{C-NMR}$ ($\text{DMSO-}d_6$) δ (ppm): 158.8 (2-Cim), 151.4 (1-Car), 134.8 (4-Car), 127.0 (3,5-Car), 125.4 (2,6-Car), 63.9 (5-Cim), 49.4 (4-Cim), 42.5 (2,8,9-Cad), 36.1 (4,6,10-Cad), 35.7 (1-Cad), 29.1 (CH_3), 28.3 (3,5,7-Cad). Anal. calc. for $\text{C}_{20}\text{H}_{28}\text{BrN}_3$ (%): C, 61.54; H, 7.23; N, 10.76, found: (%) C, 61.25; H, 7.42; N, 10.70.

4,5-Dihydro-2-[4-(1-tricyclo[3.3.1.1^{3,7}]decyl)phenyl]-1H-imidazole (1d). To a stirring solution of aldehyde **9** (240 mg, 1 mmol) in *tert*-butyl alcohol (10 mL), ethylenediamine (66 mg, 1.1 mmol) was added and the reaction mixture was stirred at rt for 30 min. Subsequently, K_2CO_3 (417 mg, 3 mmol) and iodine (3.18 mg, 1.25 mmol) were added and the reaction mixture was heated to 70 °C for 3 h. In the case of complete discoloration, the excess iodine is destroyed by adding sodium metabisulphite under cooling. *Tert*-butanol is removed *in vacuo*, water is added to the residue and the aqueous layer is extracted with chloroform. The combined organic layers are washed with water, dried over Na_2SO_4 and concentrated under vacuum to afford 280 mg of **1d**. Yield almost quantitative. M.p.: 161–163 °C. The product was transformed into fumarate. M.p.: >250 °C (ethanol-diethyl ether); $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 7.73–7.75 (d, 2H, $J = 8.4$ Hz, 2,6-Har), 7.37–7.39 (d, 2H, $J = 8.4$ Hz, 3,5-Har), 5.04 (br.s, 1H, 1-Him), 3.78 (s, 4H, 4,5-Him), 2.09 (br. s, 3H, 3,5,7-Had), 1.89–1.90 (m, 6H, 2,8,9-Had), 1.72–1.81 (m, 6H, 4,6,10-Had). $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ (ppm): 165.0 (2-Cim), 154.1 (1,4-Car), 127.1 (2,6-Car), 125.2 (3,5-Car), 50.0 (4,5-Cim), 43.1 (2,8,9-Cad), 36.8 (4,6,10-Cad), 36.6 (1-Cad), 29.0 (3,5,7-Cad). Anal. calcd. for $\text{C}_{23}\text{H}_{28}\text{N}_2\text{O}_4$ (%): C, 69.67; H, 7.12; N, 7.07; found (%) C, 69.40; H, 7.27; N, 6.88.

General procedure of preparation of hydroxybenzimidamides 12, 16, 19. A solution of hydroxylamine hydrochloride (4.53 mmol) and DIPEA (4.53



mmol) in EtOH (20 mL) was stirred at rt for 1 h. Then, a solution of the respective benzonitrile **12**, **14**, **19** (1.51 mmol) in EtOH (50 mL) was added to the reaction mixture. The reaction mixture was heated to 60 °C for 16 h. Then, the solvent was removed under vacuum, water was added to the reaction mixture and the aqueous phase was extracted with AcOEt. The combined organic phases were dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography with an eluent mixture of 20% methanol in dichloromethane to afford the respective benzimidamides as white solids.

(Z)-4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)-N-hydroxybenzimidamide (13). *N*-Hydroxybenzimidamide **13** was prepared, as described in the general method, using benzonitrile **12**. Yield: 78%. M.p.: 223–224 °C. ¹H NMR (600 MHz, DMSO-*d*₆), δ (ppm): 9.52 (s, 1H, OH), 7.60–7.59 (d, *J* = 8.5 Hz, 2H, 2,6-Had), 7.35–7.34 (d, *J* = 8.5 Hz, 2H, 3,5-Had), 5.72 (s, 2H, NH₂), 2.06–2.05 (s, 3H, 3,5,7-Had), 1.86 (m, 6H, 2,8,9-Had), 1.74–1.73 (m, 6H, 4,6,10-Had). ¹³C NMR (151 MHz, DMSO-*d*₆), δ (ppm): 151.4 (4-Car), 150.7 (N=C=N), 124.3 (1-Car), 125.1 (2,6-Car), 124.3 (3,5-Car), 42.3 (2,8,9-Cad), 36.0 (4,6,10-Cad), 35.6 (1-Cad), 28.1 (3,5,7-Cad).

4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)phenoxy]-N'-hydroxybenzimidamide (17). *N*-Hydroxybenzimidamide **17** was prepared, as described in the general method, using benzonitrile **16**. Yield: 71%. M.p.: 217–218 °C. There is a mixture of *E* and *Z* isomers, with the *Z* isomer 72% and the *E* isomer 28%. *Z* isomer: ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 9.54 (s, 1H, OH), 7.67–7.65 (d, *J* = 8.8 Hz, 2H, 2',6'-Har), 7.38–7.36 (d, *J* = 8.8 Hz, 2H, 3,5-Har), 6.98–6.94 (m, 4H, 3',5',2,6-Har), 5.75 (s, 2H, NH₂), 2.06–2.04 (br.s, 3H, 3,5,7-Had), 1.86–1.85 (m, 6H, 2,8,9-Had), 1.73 (m, 6H, 4,6,10-Had). ¹³C NMR (101 MHz, DMSO-*d*₆), δ (ppm): 157.41 (4'-Car), 153.68 (1-Car), 150.15 (N=C=N), 146.17 (4-Car), 128.07 (1'-Car), 126.92 (2',6'-Car), 126.10 (3,5-Car), 118.35 (2,6-Car), 117.74 (3',5'-Car), 42.49 (2,8,9-Cad), 35.92 (4,6,10-Cad) – 35.20 (1-Cad), 28.10 (3,5,7-Cad). *E* isomer: ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 9.54 (s, 1H, OH), 7.89–7.86 (d, *J* = 8.7 Hz, 2H, 2',6'-Har), 7.40–7.38 (d, *J* = 8.8 Hz, 2H, 3,5-Har), 7.02–6.97 (m, 4H, 3',5',2,6-Har), 5.75 (s, 2H, NH₂), 2.06–2.04 (br.s, 3H, 3,5,7-Had), 1.86–1.85 (m, 6H, 2,8,9-Had), 1.73 (m, 6H, 4,6,10-Had). ¹³C NMR (101 MHz, DMSO-*d*₆), δ (ppm): 167.0 (N=C=N), 159.5 (4'-Car), 153.1 (1-Car), 146.7 (4-Car), 129.4 (2',6'-Car), 128.6 (1'-Car), 126.2 (3,5-Car), 118.9 (2,6-Car), 116.9 (3',5'-Car), 42.5 (2,8,9-Cad), 35.9 (4,6,10-Cad) – 35.2 (1-Cad), 28.1 (3,5,7-Cad).

(Z)-4-[[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)benzyl]oxy]-N'-hydroxybenzimidamide (20). *N*-Hydroxybenzimidamide **20** was prepared, as described in the general method, using benzonitrile **19**. Yield 76%. M.p.: 218–219 °C (methanol-diethyl ether); ¹H NMR (600 MHz, DMSO-*d*₆), δ (ppm): 9.45 (s, 1H, OH), 7.60–7.58 (d, *J* = 8.8 Hz, 2H, 2',6'-Har), 7.37 (s, 4H, 2,3,5,6-Har), 6.69–6.98 (d, *J* = 8.8 Hz, 2H, 3',5'-Har), 5.72 (s, 2H, NH₂), 5.07 (s, 2H, α -H), 2.06 (br.s, 3H, 3,5,7-Had), 1.86–1.85 (m, 6H, 2,8,9-Had), 1.76–1.70 (m, 6H, 4,6,10-Had). ¹³C NMR (151 MHz, DMSO-*d*₆), δ (ppm): 159.4 (4'-Car), 151.0 (N=C=N), 134.4 (4-Car), 129.7 (1-Car), 128.1 (2,6-Car), 127.1

(2',6'-Car), 126.3 (1'-Car), 125.2 (3,5-Car), 114.7 (3',5'-Car), 69.4 (α -C), 43.0 (2,8,9-Cad), 36.6 (4,6,10-Cad), 36.1 (1-Cad), 28.7 (3,5,7-Cad).

General procedure of preparation of benzimidamide 2a, 3a, 3b. To a solution of the respective *N'*-hydroxybenzimidamide **13**, **17**, **20** (0.27 mmol) in AcOH (6.75 mL) was added acetic anhydride (0.35 mmol) and the reaction mixture was stirred under argon at rt for 1.5 h. Zinc powder (4.05 gr-at) was then added and the reaction mixture was further stirred for 24 h under argon at rt. By the end of the reaction, the zinc was removed by filtration and washed with AcOH and methanol. The filtrate was concentrated and the resulting residue was dissolved in methanol, a solution of NaOH (10 mL, 5 M) was added (pH > 7) and the resulting solution was stirred for 1 h. Subsequently, the solvent was removed under vacuum. Water and AcOEt was added to the reaction mixture and the aqueous phase was extracted with AcOEt. The combined organic phases were washed with water, dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by gradient flash column chromatography with an eluent of 5% to 20% methanol in dichloromethane to afford the respective benzimidamine as white crystal.

4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)benzimidamide diacetate (2a). Benzimidamide **2a** was prepared, as described in the general method, using *N'*-hydroxybenzimidamide **13**. Elution with methanol/dichloromethane/acetic acid, 94:5:1 afforded **2a** as a white crystal solid. Yield: 56%. M.p.: >250 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 10.21 (s, 3H, NH₂, NH), 7.74 (d, *J* = 8.4 Hz, 2H, 2,6-Har), 7.56–7.54 (d, *J* = 8.4 Hz, 2H, 3,5-Har), 2.09–2.06 (s, 3H, 3,5,7-Had), 1.89–1.88 (m, 6H, 2,8,9-Had), 1.76–1.70 (m, 12H, 4,6,10-Had, CH₃). ¹³C NMR (101 MHz, DMSO-*d*₆), δ (ppm): 177.1 (CO), 166.1 (N=C=N), 156.3 (4-Car), 127.6 (2,6-Car), 127.2 (1-Car), 125.5 (3,5-Car), 42.4 (2,8,9-Cad), 36.4 (1-Cad), 36.2 (4,6,10-Cad), 28.4 (3,5,7-Cad), 24.9 (CH₃); Anal. calc. for C₂₁H₃₀N₂O₄ (%): C, 67.35; H, 8.08; N, 7.48, found: (%): C, 67.55; H, 8.38; N, 7.28.

4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)phenoxy]benzimidamide (3a). Benzimidamide **3a** was prepared, as described in the general method, using *N'*-hydroxybenzimidamide **17** and afforded as a white crystal solid. Yield: 48%. M.p.: 238–239 °C (methanol-diethyl ether); ¹H NMR (400 MHz, CD₃OD), δ (ppm): 7.74 (d, *J* = 9.2 Hz, 2H, 2',6'-Har), 7.43 (d, *J* = 8.0 Hz, 2H, 3,5-Har), 7.02 (m, 4H, 2,6,3',5'-Har), 2.12–2.11 (br.s, 3H, 3,5,7-Had), 1.97–1.96 (br.s, 6H, 2,8,9-Had), 1.85–1.82 (m, 6H, 4,6,10-Had). ¹³C NMR (101 MHz, CD₃OD), δ (ppm): 167.8 (N=C=N), 163.3 (4'-Car), 155.1 (1-Car), 149.6 (4-Car), 130.6 (2',6'-Car), 128.0 (3,5-Car), 121.1 (2,6-Car), 118.9 (3',5'-Car), 44.9 (2,8,9-Cad), 38.3 (4,6,10-Cad), 37.5 (1-Cad), 30.9 (3,5,7-Cad); Anal. calc. for C₂₃H₂₆N₂O (%): C, 79.73; H, 7.56; N, 8.09, found: (%): C, 79.93; H, 7.76; N, 8.19.

4-[[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)benzyl]oxy]benzimidamide (3b). Benzimidamide **3b** was prepared, as described in the general method, using *N'*-hydroxybenzimidamide **20**. Yield: 49%. M.p.: 243–244 °C (dec). ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 9.10 (s, 3H, NH₂, NH), 7.83 (d, *J* = 8.4 Hz, 2H, 2',6'-



Har), 7.39 (s, 4H, 2,3,5,6-Har), 7.22 (d, $J = 8.5$ Hz, 2H, 3',5'-Har), 5.19 (s, 2H, α -H), 2.05 (br.s, 3H, 3,5,7-Had), 1.85 (br.s, 6H, 2,8,9-Had), 1.73 (br.s, 6H, 4,6,10-Had). ^{13}C NMR (101 MHz, DMSO- d_6), δ (ppm): 164.49 (NH₂CNH), 162.5 (4'-Car), 150.6 (4-Car), 133.1 (1-Car), 130.0 (2',6'-Car), 127.6 (2,6-Car), 124.6 (3,5-Car), 119.5 (1'-Car), 114.9 (3',5'-Car), 69.3 (α -C), 42.4 (2,8,9-Cad), 35.9 (4,6,10-Cad), 35.5 (1-Cad), 28.1 (3,5,7-Cad); Anal. calc. for C₂₄H₂₈N₂O (%): C, 79.96; H, 7.83; N, 7.77, found: (%) C, 80.26; H, 8.03; N, 7.97.

General procedure of preparation of benzylethers 16, 19. Sodium hydride (5.15 mmol, 60%) was added to a solution of the respective alcohol **15**, **18** (1.03 mmol) in anhydrous DMF (5 mL) and is allowed to stir for 10–15 min. Subsequently, a solution of 4-fluorobenzonitrile (1.03 mmol) in anhydrous DMF (5 mL) was added into the reaction mixture which was heated to 100 °C for 24 h. The reaction was quenched with water and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with water and dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography with an eluent mixture of 10% EtOAc in *n*-hexane to afford the respective benzylether as white crystal product.

4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)phenoxy]benzonitrile (16). Benzonitrile **16** was prepared, as described in the general method, using phenol **15**.³² Yield 66%. M.p.: 206–207 °C; ^1H NMR (400 MHz, CDCl₃), δ (ppm): 7.59–7.57 (d, $J = 8.9$ Hz, 2H, 2',6'-Har), 7.40–7.38 (d, $J = 8.8$ Hz, 2H, 3,5-Har), 7.01 (d, $J = 2.3$ Hz, 2H, 2,6-Har), 6.99–6.98 (d, $J = 2.3$ Hz, 2H, 3',5'-Har), 2.12 (br.s, 3H, 3,5,7-Had), 1.92 (m, 6H, 2,8,9-Had), 1.83–1.74 (m, 6H, 4,6,10-Had). ^{13}C NMR (101 MHz, CDCl₃), δ (ppm): 162.5 (4'-Car), 152.8 (1-Car), 148.9 (4-Car), 134.5 (2',6'-Car), 127.1 (3,5-Car), 120.4 (2,6-Car), 119.4 (CN), 118.2 (3',5'-Car), 105.9 (1'-Car), 43.8 (2,8,9-Had), 37.2 (4,6,10-Had), 36.5 (1-Had), 29.4 (3,5,7-Had).

4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)benzyl]oxy}benzonitrile (19). Benzonitrile **19** was prepared, as described in the general method, using methanol **18**.³² Yield 62%. M.p.: 173–174 °C. ^1H NMR (600 MHz, CDCl₃), δ (ppm): 7.59–7.58 (d, $J = 8.9$ Hz, 2H, 2',6'-Har), 7.41–7.40 (d, $J = 6.3$ Hz, 2H, 3,5-Har), 7.37–7.35 (d, $J = 8.4$ Hz, 2H, 2,6-Har), 7.03–7.01 (d, $J = 8.9$ Hz, 2H, 3',5'-Har), 5.08 (s, 2H, α -H), 2.11 (br.s, 3H, 3,5,7-Had), 1.93–1.91 (m, 6H, 2,8,9-Had), 1.82–1.72 (m, 6H, 4,6,10-Had). ^{13}C NMR (151 MHz, CDCl₃), δ (ppm): 162.5 (4'-Car), 152.2 (4-Car), 134.4 (2',6'-Car), 133.0 (1-Car), 127.9 (2,6-Car), 125.7 (3,5-Car), 119.6 (CN), 115.9 (1'-Car), 70.6 (α -C), 43.5 (2,8,9-Cad), 37.1 (4,6,10-Cad), 36.5 (1-Cad), 29.3 (3,5,7-Cad).

2-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)phenyl]acetimidamide (2b). To a stirring solution of ammonium chloride (42 mg, 0.79 mmol) in toluene (0.4 mL) at 0 °C, a solution of trimethylaluminum in toluene (0.79 mL, 1 M, 0.79 mmol) was added dropwise. The reaction mixture was stirred at rt for 2 h. Acetonitrile **14** (200 mg, 0.7 mmol) was added, and the resulting reaction mixture was heated to 80 °C for 19 h. The reaction mixture was cooled and the aluminum complex was decomposed by carefully pouring the solution into a slurry of silica gel in chloroform. The resulting mixture was

stirred at rt for 10 min. Then, the silica gel was filtered off and washed with methanol. The combined filtrates were concentrated under vacuum. The residue was purified by flash column chromatography with an eluent mixture of 10% methanol in dichloromethane and afforded 97 mg of **2b** as a white crystal solid. Yield: 36%. M.p.: 240–242 °C. ^1H NMR (600 MHz, DMSO- d_6), δ (ppm): 9.34–8.93 (br.d, 3H, NH₂, NH), 7.40 (d, $J = 7.8$ Hz, 2H, 2,6-Had), 7.31 (d, $J = 7.9$ Hz, 2H, 3,5-Had), 3.68 (s, 2H, α -H), 2.02 (s, 3H, 3,5,7-Had), 1.82–1.70 (m, 12H, 2,8,9,4,6,10-Had). ^{13}C NMR (151 MHz, DMSO- d_6), δ (ppm): 169.7 (N–C=N), 150.4 (4-Car), 131.6 (1-Cad), 128.9 (2,6-Cad), 125.2 (3,5-Car), 42.9 (2,8,9-Cad), 37.2 (α -C), 36.4 (4, 6, 10-Cad), 35.8 (1-Cad), 28.5 (3,5,7-Cad); Anal. calc. for C₁₈H₂₄N₂ (%): C, 80.55; H, 9.01; N, 10.44, found: (%) C, 80.85; H, 8.23; N, 8.07.

General procedure for the preparation of benzaldehydes 21–23. To a stirring solution of the respective phenol **15** (2.63 mmol) in DMF (10 mL), the corresponding 4-fluorobenzaldehyde (7.9 mmol) and K₂CO₃ (7.9 mmol) were added. The reaction mixture was heated at 160 °C for 24 h. Then, EtOAc and HCl solution (1N) were added to the reaction mixture and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography with an eluent mixture of 10% EtOAc in *n*-hexane to afford a product, which was further treated with ice-cold hexane to give the desired products **21–23**.

4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)phenoxy]benzaldehyde (21). Benzaldehyde **21** was prepared, as described in the general procedure, using 4-fluorobenzaldehyde. Yield 55%. M.p.: 159 °C. ^1H NMR (600 MHz, CDCl₃), δ (ppm): 10.28 (s, 1H, CHO), 7.81 (d, $J = 8.7$ Hz, 1H, 5'-Har), 7.33 (d, $J = 8.6$ Hz, 2H, 3,5-Har), 6.94 (d, $J = 8.6$ Hz, 2H, 2,6-Har), 6.89 (d, $J = 2.2$ Hz, 1H, 3'-Har), 6.85 (dd, $J = 8.7, 2.2$ Hz, 1H, 6'-Har), 2.05 (s, 3H, 3,5,7-Had), 1.86–1.87 (m, 6H, 2,8,9-Had), 1.67–1.71 (m, 6H, 4,6,10-Had). ^{13}C NMR (151 MHz, CDCl₃), δ (ppm): 188.7 (CHO), 163.8 (1'-Car), 152.1 (4-Car), 148.9 (4'-Car), 139.8 (C-Cl), 131.2 (5'-Car), 127.2 (1-Car), 126.9 (3,5-Car), 120.2 (2,6-Car), 118.3 (3'-Car), 116.2 (6'-Car), 43.4 (2,8,9-Cad), 36.9 (4,6,10-Cad), 36.2 (1-Cad), 29.1 (3,5,7-Cad).

4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)phenoxy]-2-chlorobenzaldehyde (22). Benzaldehyde **22** was prepared, as described in the general procedure, using 2-chloro-4-fluorobenzaldehyde. Yield 49%. M.p.: 165–167 °C. ^1H NMR (600 MHz, CDCl₃), δ (ppm): 11.35 (s, 1H, CHO), 7.88 (d, $J = 8.7$ Hz, 1H, 5'-Har), 7.40 (d, $J = 8.6$ Hz, 2H, 3,5-Har), 7.02 (d, $J = 8.6$ Hz, 2H, 2,6-Har), 6.96 (d, $J = 2.2$ Hz, 1H, 3'-Har), 6.92 (dd, $J = 8.7, 2.2$ Hz, 1H, 6'-Har), 2.13 (s, 3H, 3,5,7-Had), 1.93 (m, 6H, 2,8,9-Had), 1.75–1.83 (m, 6H, 4,6,10-Had). ^{13}C NMR (151 MHz, CDCl₃), δ (ppm): 188.7 (CHO), 163.8 (1'-Car), 152.1 (4-Car), 148.9 (4'-Car), 139.8 (C-Cl), 131.2 (5'-Car), 127.2 (1-Car), 126.9 (3,5-Car), 120.2 (2,6-Car), 118.3 (3'-Car), 116.1 (6'-Car), 43.4 (2,8,9-Cad), 36.8 (4,6,10-Cad), 36.2 (1-Cad), 29.1 (3,5,7-Cad).

4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)phenoxy]-3-chlorobenzaldehyde (23). Benzaldehyde **23** was prepared, as described in the



general procedure, using 3-chloro-4-fluorobenzaldehyde. Yield 74%. M.p.: 167–168 °C. ^1H NMR (600 MHz, CDCl_3) δ (ppm): 9.88 (s, 1H, CHO), 7.98 (d, $J = 2.0$ Hz, 1H, 2'-Har), 7.66 (dd, $J = 8.5, 2.0$ Hz, 1H, 6'-Har), 7.41–7.39 (m, 2H, 3',5'-Har), 7.03–7.01 (m, 2H, 2,6-Har), 6.93 (d, $J = 8.5$ Hz, 1H, 5'-Har), 2.11 (s, 3H, 3,5,7-Had), 1.93–1.92 (m, 6H, 2,8,9-Had), 1.82–1.74 (m, 6H, 4,6,10-Had). ^{13}C NMR (151 MHz, CDCl_3) δ (ppm): 189.8 (CHO), 159.1 (1'-Car), 152.6 (1-Car), 148.7 (4-Car), 132.1 (2'-Car), 131.9 (Cl-C), 129.8 (6'-Car), 126.8 (3,5-Car), 125.2 (4'-Car), 119.7 (2,6-Car), 117.6 (5'-Car), 43.4 (2,8,9-Cad), 36.8 (4,6,10-Cad), 36.2 (1-Cad), 29.0 (3,5,7-Cad).

General procedure for the preparation of aminoguanidine hydrazones 4a, 5a–c. To a stirring solution of the respective benzaldehyde **9**, **21–23** (0.42 mmol) and aminoguanidine bicarbonate (0.42 mmol) in EtOH (5 mL), con. HCl (six drops) were added and the reaction mixture was heated to reflux for 24 h. Then, the solvent was evaporated and chloroform was added to the solid residue. The resulting mixture was filtered. The filtrate was concentrated under vacuum and the product was crystallised by anhydrous diethyl ether.

2-(E)-4-[(1-Tricyclo[3.3.1.1^{3,7}]decyl)benzylidene]hydrazine-1-carboxyimidamide hydrochloride (4a). Aminoguanidine hydrazone **4a** was prepared as described in the general procedure using benzaldehyde **9**. Yield 46%. M.p.: >250 °C; ^1H -NMR (400 MHz, $\text{DMSO}-d_6$) δ (ppm): 11.74 (s, 1H, =N-NH), 8.13 (s, 1H, α -H), 7.78 (d, $J = 8.4$ Hz, 2H, 2,6-Har), 7.68 (br.s 4H, NH_2), 7.43 (d, $J = 8.4$ Hz, 2H, 3,5-Har), 2.06 (s, 3H, 3,5,7-Had), 1.87–1.88 (m, 6H, 2,8,9-H), 1.78–1.74 (m, 6H, 4,6,10-Had). ^{13}C -NMR (101 MHz, $\text{DMSO}-d_6$) δ (ppm): 155.0 (C=NH), 153.3 (1-Car), 146.8 (α -C), 130.5 (4-Car), 127.3 (2,6-Car), 124.8 (3,5-Car), 42.1 (2,8,9-Cad), 35.9 (1,6-Cad), 35.8 (4,10-Cad), 28.0 (3,5,7-Cad); Anal. calc. for $\text{C}_{18}\text{H}_{25}\text{ClN}_4$ (%): C, 64.95; H, 7.57; N, 16.83, found: (%) C, 65.25; H, 7.77; N, 7.87.

2-[(E)-4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)phenoxy]benzylidene]hydrazine-1-carboxyimidamide hydrochloride (5a). Aminoguanidine hydrazone **5a** was prepared as described in general procedure using benzaldehyde **21**. Yield 88%. M.p.: >250 °C (ethanol-diethyl ether); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ (ppm): 12.04 (br.s, 1H, =NH-C), 8.15 (s, 1H, α -H), 7.86 (d, $J = 8.5$ Hz, 2H, 2',6'-Har), 7.76 (br. s, 4H, NH_2), 7.39 (d, $J = 8.5$ Hz, 2H), 6.99–7.02 (m, 4H, 2,6,3',5'-Har), 2.05 (s, 3H, 3,5,7-Had), 1.86–1.87 (m, 6H, 2,8,9-Had), 1.71–1.73 (m, 6H, 4,6,10-Had). ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δ (ppm): 159.0 (C=NH), 155.4 (4'-Car), 153.4 (1-Car), 146.8 (4-Car), 146.1 (α -C), 129.5 (2',6'-Car), 128.3 (1'-Car), 126.4 (3,5-Car), 118.8 (2,6-Car), 118.0 (3',5'-Car), 42.7 (2,8,9-Cad), 36.1 (4,6,10-Cad), 35.4 (1-Cad), 28.3 (3,5,7-Cad); Anal. calc. for $\text{C}_{24}\text{H}_{29}\text{ClN}_4\text{O}$ (%): C, 67.83; H, 6.88; N, 13.18, found: (%) C, 68.13; H, 7.08; N, 13.48.

2-[(E)-4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)phenoxy]-2-chlorobenzylidene]hydrazine-1-carboxyimidamide hydrochloride (5b). Aminoguanidine hydrazone **5b** was prepared as described in general procedure using benzaldehyde **22**. Yield 83%. M.p.: >250 °C (ethanol-diethyl ether); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ (ppm): 12.23 (s, 1H, =NH-), 8.49 (s, 1H, α -H), 8.31 (d, $J = 8.8$ Hz, 1H, 5'-Har), 7.86 (br.s, 4H, NH_2), 7.44 (dd, $J = 10.5$

Hz, $J = 8.2$ Hz, 2H, 2,6-Har), 7.06–7.01 (m, 4H, 3,5,3',6'-Har), 2.06 (s, 3H, 3,5,7-Had), 1.87 (m, 6H, 2,8,9-Had), 1.71–1.73 (m, 6H, 4,6,10-Had). ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δ (ppm): 159.6 (C=NH), 155.3 (1-Car), 152.7 (4'-Car), 147.4 (4-Car), 142.2 (α -C), 134.3 (C-Cl), 129.3 (5'-Car), 126.6 (2,6-Car), 125.4 (1'-Car), 119.2 (3,5-Car), 118.0 (6'-Car), 117.3 (3'-Car), 42.6 (2,8,9-Cad), 36.1 (4,6,10-Cad), 35.5 (1-Cad), 28.3 (3,5,7-Cad); Anal. calc. for $\text{C}_{24}\text{H}_{28}\text{Cl}_2\text{N}_4\text{O}$ (%): C, 62.75; H, 6.14; N, 12.20, found: (%) C, 63.05; H, 6.24; N, 12.10.

2-[(E)-4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)phenoxy]-3-chlorobenzylidene]hydrazine-1-carboxyimidamide hydrochloride (5c). Aminoguanidine hydrazone **5c** was prepared as described in general procedure using benzaldehyde **23**. Yield 68%. M.p.: >250 °C (ethanol-diethyl ether); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ (ppm): 11.97 (s, 1H, =N-NH-), 8.26 (d, $J = 1.9$ Hz, 1H, 2'-Har), 8.14 (s, 1H, 6'-Har), 8.23–7.43 (br. s, 4H, NH_2), 7.71 (d, $J = 1.9$ Hz, 2H, 3,5-Har), 7.38 (m, 1H, 5'-Har), 6.95–7.02 (m, 2H, 2,6-Har), 2.06 (s, 3H, 3,5,7-Had), 1.85 (m, 6H, 2,8,9-Had), 1.70–1.72 (m, 6H, 4,6,10-Had). ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δ (ppm): 155.4 (C=NH), 153.6 (1-Car), 146.8 (4-Car), 144.9 (2'-Car), 130.3 (1'-Car), 128.7 (6'-Car, α -C), 126.5 (3,5-Car), 124.8 (C-Cl), 119.9 (5'-Car), 117.8 (2,6-Car), 42.7 (2,8,9-Cad), 36.1 (4,6,10-Cad), 35.5 (1-Cad), 28.3 (3,5,7-Cad); Anal. calc. for $\text{C}_{24}\text{H}_{28}\text{Cl}_2\text{N}_4\text{O}$ (%): C, 62.75; H, 6.14; N, 12.20, found: (%) C, 63.95; H, 6.34; N, 12.00.

2-[(E)-4-[4-(1-Tricyclo[3.3.1.1^{3,7}]decyl)benzylidene]hydrazine-1-carboxamide hydrochloride (4b). To a stirring solution of benzaldehyde **9** (250 mg, 1.04 mmol) and semicarbazide hydrochloride (116 mg, 1.04 mmol) in EtOH (1 mL), conc. HCl (six drops) were added and the reaction mixture was heated to reflux for 6 h and left at rt overnight. Subsequently, the solvent is evaporated and anhydrous diethyl ether was added to the solid residue forming crystals, 160 mg, yield 46%. M.p.: >250 °C (methanol/chloroform/propanol); ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ (ppm): 10.17 (s, 1H, =N-NH), 7.80 (s, 1H, α -H), 7.62 (d, $J = 8.5$ Hz, 2H, 2,6-Har), 7.35 (d, $J = 8.5$ Hz, 2H, 3,5-Har), 6.43 (br.s, 2H, NH_2), 2.05 (s, 3H, 3,5,7-Had), 1.86–1.87 (m, 6H, 2,8,9-Had), 1.73–1.74 (m, 6H, 4,6,10-Had). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ (ppm): 156.7 (C=O), 151.9 (1-Car), 139.2 (α -C), 132.1 (4-Car), 126.4 (2,6-Car), 124.9 (4-Car), 42.4 (2,8,9-Cad), 36.1 (4,6,10-Cad), 35.8 (1-Cad), 28.3 (3,5,7-Cad); Anal. calc. for $\text{C}_{18}\text{H}_{24}\text{ClN}_3\text{O}$ (%): C, 64.76; H, 7.25; N, 12.59, found: (%) C, 63.96; H, 7.55; N, 12.49.

General procedure for the preparation of thiosemicarbazides 4c, 6a–c. To a stirring solution of the respective benzaldehyde **9**, **21–23** (0.3 mmol) and thiosemicarbazide (0.3 mmol) in EtOH (10 mL), con. HCl (six drops) were added and the reaction mixture was heated to reflux for 24 h. Then, the solvent was concentrated under vacuum forming a crystal precipitate that was recrystallized by a mixture of solvents dichloromethane-EtOH, affording the pure product.

2-(E)-4-[(1-Tricyclo[3.3.1.1^{3,7}]decyl)benzylidene]hydrazine-1-carbothiamide hydrochloride (4c). Thiosemicarbazide **4c** was prepared as described in the general procedure. Yield 33%. M.p.: >250 °C (chloroform-EtOH); ^1H NMR (600 MHz,



DMSO- d_6) δ 11.37 (s, 1H, =N-NH), 8.16 (s, 1H, NH), 8.02 (s, 1H, α -H), 7.92 (s, 1H, NH), 7.72 (d, J = 8.4 Hz, 2H, 2,6-Har), 7.39 (d, J = 8.4 Hz, 2H, 3,5-Har), 2.06 (s, 3H, 3,5,7-Had), 1.86–1.87 (m, 6H, 2,8,9-Had), 1.73–1.74 (m, 6H, 4,6,10-Had). ^{13}C NMR (151 MHz, DMSO- d_6) δ 177.8 (C=S), 152.8 (1-Car), 142.3 (α -C), 131.5 (4-Car), 127.2 (2,6-Car), 125.0 (3,5-Car), 42.4 (2,8,9-Cad), 36.1 (4,6,10-Cad), 35.9 (1-Cad), 28.2 (3,5,7-Cad); Anal. calc. for $\text{C}_{18}\text{H}_{24}\text{ClN}_3\text{S}$ (%): C, 61.78; H, 6.91; N, 12.01, found: (%) C, 62.08; H, 7.11; N, 12.31.

2- $\{[(E)-4-[4-(1\text{-Tricyclo}[3.3.1.1^{3,7}]\text{decyl})\text{phenoxy}]\text{benzylidene}\}\text{hydrazine-1-carbothioamide hydrochloride (6a)}$. Thiosemicarbazide **6a** was prepared as described in the general procedure using benzaldehyde **21**. Yield 52%. M.p.: >250 °C (dichloromethane-ethanol); ^1H NMR (600 MHz, DMSO- d_6) δ (ppm): 11.46 (s, 1H, =N-NH-), 8.23 (s, 1H, NH), 8.10 (s, 1H, α -H), 8.02 (s, 1H, NH), 7.88 (d, J = 8.7 Hz, 2H, 2',6'-Har), 7.48 (d, J = 8.8 Hz, 2H, 3',5'-Har), 7.07 (dd, J = 16.4, 8.8 Hz, 4H, 2,6,3',5'-Har), 2.14 (s, 3H, 3,5,7-Had), 1.94–1.95 (m, 6H, 2,8,9-Had), 1.81–1.82 (m, 6H, 4,6,10-Had). ^{13}C NMR (151 MHz, DMSO- d_6) δ (ppm): 177.8 (C=S), 158.6 (4'-Car), 153.5 (1-Car), 146.7 (4-Car), 141.6 (α -C), 129.1 (2',6'-Car), 129.1 (1'-Car), 126.4 (3,5-Car), 118.8 (2,6-Car), 118.0 (3',5'-Car), 42.7 (2,8,9-Cad), 36.1 (4,6,10-Cad), 35.5 (1-Cad), 28.3 (3,5,7-Cad); Anal. calc. for $\text{C}_{24}\text{H}_{28}\text{ClN}_3\text{OS}$ (%): C, 65.22; H, 6.39; N, 9.51, found: (%) C, 65.52; H, 6.59; N, 9.61.

2- $\{[(E)-4-[4-(1\text{-Tricyclo}[3.3.1.1^{3,7}]\text{decyl})\text{phenoxy}]\text{-2-chlorobenzylidene}\}\text{hydrazine-1-carbothioamide hydrochloride (6b)}$. Thiosemicarbazide **6b** was prepared as described in the general procedure using benzaldehyde **22**. Yield 81%. M.p.: >250 °C (dichloromethane-ethanol); ^1H NMR (400 MHz, DMSO- d_6) δ (ppm): 13.12 (s, =N-NH-), 8.37 (s, 1H, α -H), 7.88–7.91 (m, 1H, 5'-Har), 7.51 (s, 2H, NH₂), 7.27–7.31 (m, 2H, 2,6-Har), 6.88–6.92 (m, 2H, 3,5-Har), 6.80–6.83 (m, 2H, 3',6'-Har), 2.03 (s, 3H, 3,5,7-Had), 1.83 (m, 6H, 2,8,9-Had), 1.69–1.71 (m, 6H, 4,6,10-Had). ^{13}C NMR (101 MHz, DMSO- d_6) δ (ppm): 177.8 (C=S), 158.9 (1-Car), 152.0 (4'-Car), 147.0 (4-Car), 138.8 (α -C), 134.3 (C-Cl), 127.5 (5'-Car), 125.7 (2,6-Car), 125.1 (1'-Car), 118.6 (3,5-Car), 117.4 (6'-Car), 116.0 (3'-Car), 42.4 (2,8,9-Cad), 35.8 (4,6,10-Cad), 35.0 (1-Cad), 27.9 (3,5,7-Cad); Anal. calc. for $\text{C}_{24}\text{H}_{27}\text{Cl}_2\text{N}_3\text{OS}$ (%): C, 60.50; H, 5.71; N, 8.82, found: (%) C, 60.80; H, 5.81; N, 9.02.

2- $\{[(E)-4-[4-(1\text{-Tricyclo}[3.3.1.1^{3,7}]\text{decyl})\text{phenoxy}]\text{-3-chlorobenzylidene}\}\text{hydrazine-1-carbothioamide hydrochloride (6c)}$. Thiosemicarbazide **6c** was prepared as described in general procedure using benzaldehyde **23**. Yield 72%. M.p.: >250 °C (dichloromethane-ethanol); ^1H NMR (400 MHz, CDCl_3 + DMSO- d_6) δ (ppm): 11.41 (=N-NH), 8.14 (s, 1H, NH), 8.13 (s, 1H, 2'-Har), 8.05 (s, 1H, NH), 7.97 (s, 1H, α -H), 7.55 (d, J = 8.0 Hz, 1H, 6'-Har), 7.30–7.33 (m, 2H, 3,5-Har), 6.90–6.93 (m, 3H, 2,6,5'-Har), 2.05 (s, 3H, 3,5,7-Had), 1.85 (m, 6H, 2,8,9-Had), 1.71–1.72 (m, 6H, 4,6,10-Had). ^{13}C NMR (101 MHz, CDCl_3 + DMSO- d_6) δ (ppm): 178.0 (C=S), 153.50 (1-Car), 153.1 (4'-Car), 146.5 (4-Car), 140.0 (α -C), 130.9 (1'-Car), 128.2 (2'-Car), 127.90 (6'-Car), 126.20 (3,5-Car), 124.8 (C-Cl), 119.5 (5'-Car), 117.6 (2,6-Car), 42.6 (2,8,9-Cad), 36.1 (4,10-Cad), 35.3 (1,6-Cad), 28.2 (3,5,7-Cad); Anal. calc. for

$\text{C}_{24}\text{H}_{27}\text{Cl}_2\text{N}_3\text{OS}$ (%): C, 60.50; H, 5.71; N, 8.82, found: (%) C, 60.70; H, 5.51; N, 8.92.

Data availability

The data supporting this article have been included into the ESI† and the experimental part of the manuscript.

Conflicts of interest

There are no conflicts to declare.

References

- J. R. Franco, G. Cecchi, M. Paone, A. Diarra, L. Grout, A. K. Ebeja, P. P. Simarro, W. Zhao and D. Argaw, *PLoS Neglected Trop. Dis.*, 2022, **16**, e0010047.
- A. K. Lindner, V. Lejon, F. Chappuis, J. Seixas, L. Kazumba, M. P. Barrett, E. Mwamba, O. Erphas, E. A. Akl, G. Villanueva, H. Bergman, P. Simarro, A. Kadima Ebeja, G. Priotto and J. R. Franco, *Lancet Infect. Dis.*, 2020, **20**, e38–e46.
- B. Nguyen, D. Hamelberg, C. Bailly, P. Colson, J. Stanek, R. Brun, S. Neidle and W. D. Wilson, *Biophys. J.*, 2004, **86**, 1028–1041.
- A. A. Farahat, A. Kumar, T. Wenzler, R. Brun, A. Paul, P. Guo, W. D. Wilson and D. W. Boykin, *Eur. J. Med. Chem.*, 2023, **252**, 115287.
- T. Sun and Y. Zhang, *Nucleic Acids Res.*, 2008, **36**, 1654–1664.
- R. T. Van Drosst and M. M. Sanders, *Antimicrob. Agents Chemother.*, 2002, **46**, 2145–2154.
- T. A. Shapiro, *Acta Trop.*, 1993, **54**, 251–260.
- K. Gehring, G. Kozlov, M. Yang and R. Fakih, *J. Biol. Chem.*, 2022, **298**, 101471.
- P. A. Nguewa, M. A. Fuertes, V. Cepeda, S. Iborra, J. Carrión, B. Valladares, C. Alonso and J. M. Pérez, *Chem. Biodiversity*, 2005, **2**, 1387–1400.
- S. Alsford, S. Eckert, N. Baker, L. Glover, A. Sanchez-Flores, K. F. Leung, D. J. Turner, M. C. Field, M. Berriman and D. Horn, *Nature*, 2012, **482**, 232–236.
- J. Song, N. Baker, M. Rothert, B. Henke, L. Jeacock, D. Horn and E. Beitz, *PLoS Pathog.*, 2016, **12**, e1005436.
- N. Baker, L. Glover, J. C. Munday, D. A. Andrés, M. P. Barrett, H. P. De Koning and D. Horn, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 10996–11001.
- M. P. Barrett, *Clin. Microbiol. Rev.*, 2025, **8**, e0015323.
- G. N. Sekhar, A. R. Georgian, L. Sanderson, G. Vizcay-Barrena, R. C. Brown, P. Muresan, R. A. Fleck and S. A. Thomas, *PLoS One*, 2017, **12**, e0173474.
- A. Baliani, V. Peal, L. Gros, R. Brun, M. Kaiser, M. P. Barrett and I. H. Gilbert, *Org. Biomol. Chem.*, 2009, **7**, 1154–1166.
- M. P. Hasne and M. P. Barrett, *J. Appl. Microbiol.*, 2000, **89**, 697–701.
- I. Papanastasiou, A. Tsotinis, G. B. Foscolos, S. R. Prathalingam and J. M. Kelly, *J. Heterocyclic Chem.*, 2008, **45**, 1401–1406.



- 18 A. Koperniku, I. Papanastasiou, G. B. Foscolos, A. Tsotinis, M. C. Taylor and J. M. Kelly, *MedChemComm*, 2013, **4**, 856–859.
- 19 A. S. Foscolos, I. Papanastasiou, A. Tsotinis, M. C. Taylor and J. M. Kelly, *ChemMedChem*, 2019, **14**, 1227–1231.
- 20 J. J. Nué-Martínez, D. Cisneros, M. del V. Moreno-Blázquez, C. Fonseca-Berzal, J. I. Manzano, D. Kraeutler, M. A. Ungogo, M. A. Aloraini, H. A. A. Elati, A. Ibáñez-Escribano, L. Lagartera, T. Herraiz, F. Gamarro, H. P. de Koning, A. Gómez-Barrio and C. Dardonville, *J. Med. Chem.*, 2023, **66**, 13452–13480.
- 21 D. A. Patrick, S. A. Bakunov, S. M. Bakunova, S. K. Jones, T. Wenzler, T. Barszcz, A. Kumar, D. W. Boykin, K. A. Werbovetz, R. Brun and R. R. Tidwell, *Eur. J. Med. Chem.*, 2013, **67**, 310–324.
- 22 X. Du, C. Guo, E. Hansell, P. S. Doyle, C. R. Caffrey, T. P. Holler, J. H. McKerrow and F. E. Cohen, *J. Med. Chem.*, 2002, **45**, 2695–2707.
- 23 P. Linciano, C. B. Moraes, L. M. Alcantara, C. H. Franco, B. Pascoalino, L. H. Freitas-Junior, S. Macedo, N. Santarem, A. Cordeiro-da-Silva, S. Gul, G. Witt, M. Kuzikov, B. Ellinger, S. Ferrari, R. Luciani, A. Quotadamo, L. Costantino and M. P. Costi, *Eur. J. Med. Chem.*, 2018, **146**, 423–434.
- 24 T. M. de Aquino, P. H. B. França, É. E. E. S. Rodrigues, I. J. S. Nascimento, P. F. S. Santos-Júnior, P. G. V. Aquino, M. S. Santos, A. C. Queiroz, M. V. Araújo, M. S. Alexandre-Moreira, R. R. L. Rodrigues, K. A. F. Rodrigues, J. D. Freitas, J. Bricard, M. R. Meneghetti, J.-J. Bourguignon, M. Schmitt, E. F. da Silva-Júnior and J. X. de Araújo-Júnior, *Med. Chem.*, 2021, **18**, 151–169.
- 25 M. Rubio-Hernández, V. Alcolea, E. Barbosa da Silva, M. A. Giardini, T. H. M. Fernandes, N. Martínez-Sáez, A. J. O'Donoghue, J. L. Siqueira-Neto and S. Pérez-Silanes, *J. Med. Chem.*, 2024, **67**, 19038–19056.
- 26 J. R. Dimmock, R. N. Puthucode, J. M. Smith, M. Hetherington, J. W. Quail, U. Pugazhenth, T. Lechler and J. P. Stables, *J. Med. Chem.*, 1996, **39**, 3984–3997.
- 27 W. Yi, R. Cao, Z. Chen, L. Yu, H. Wen, Q. Yan, L. Ma and H. Song, *Chem. Pharm. Bull.*, 2010, **58**, 752–754.
- 28 E. Da, C. Petronilho, M. Do, N. Rennó, N. G. Castro, F. Motta, R. Da Silva, A. Da, C. Pinto, D. Figueroa-Villar, E. Da Conceição Petronilho, A. Da Cunha Pinto and J. Daniel Figueroa-Villar, *J. Enzyme Inhib. Med. Chem.*, 2016, **31**, 1069–1078.
- 29 S. B. Zahra, S. Ullah, S. A. Halim, M. Waqas, N. U. Huda, A. Khan, A. Y. Binsaleh, A. F. El-kott, J. Hussain, A. Al-Harrasi and Z. Shafiq, *Sci. Rep.*, 2023, **13**, 1–14.
- 30 J. Zhu, G. Teng, D. Li, R. Hou and Y. Xia, *Med. Chem. Res.*, 2021, **30**, 1534–1540.
- 31 I. Das, A. Krzyzosiak, K. Schneider, L. Wrabetz, M. D'Antonio, N. Barry, A. Sigurdardottir and A. Bertolotti, *Science*, 2015, **348**, 239–242.
- 32 A. Koperniku, A.-S. Foscolos, I. Papanastasiou, G. B. Foscolos, A. Tsotinis and D. Schols, *Lett. Org. Chem.*, 2016, **13**, 171–176.
- 33 D. Tataridis, G. Fytas, A. Kolocouris, C. Fytas, N. Kolocouris, G. B. Foscolos, E. Padalko, J. Neyts and E. De Clercq, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 692–696.
- 34 A. Koperniku, I. Papanastasiou, G. B. Foscolos, A. Tsotinis, M. C. Taylor and J. M. Kelly, *MedChemComm*, 2013, **4**, 856–859.
- 35 M. Ishihara and H. Togo, *Tetrahedron*, 2007, **63**, 1474–1480.
- 36 J. S. An, W. K. Shin and D. K. An, *Bull. Korean Chem. Soc.*, 2015, **36**, 2928–2931.
- 37 M. B. Johansen, O. R. Gedde, T. S. Mayer and T. Skrydstrup, *Org. Lett.*, 2020, **22**, 4068–4072.
- 38 M.-O. Georgiadis, V. Kourbeli, I. P. Papanastasiou, A. Tsotinis, M. C. Taylor and J. M. Kelly, *RSC Med. Chem.*, 2020, **11**, 72–84.
- 39 A. R. Tunoori, J. M. White and G. I. Georg, *Org. Lett.*, 2000, **2**, 4091–4093.
- 40 J. M. White, A. R. Tunoori, B. J. Turunen and G. I. Georg, *J. Org. Chem.*, 2004, **69**, 2573–2576.
- 41 F. Pilathottathil, D. Vineet Kumar and A. Kaliyamoorthy, *Synth. Commun.*, 2020, **50**, 1622–1632.
- 42 R. I. Khusnutdinov, N. A. Shchadneva and L. F. Khisamova, *Russ. J. Org. Chem.*, 2015, **51**, 1545–1550.
- 43 S. Behrouz, N. Kühl and C. D. Klein, *Tetrahedron Lett.*, 2021, **81**, 153342.
- 44 R. S. Garigipati, *Tetrahedron Lett.*, 1990, **31**, 1969–1972.
- 45 R. Vande Voorde, E. Dzalamidze, D. Nelson and L. Danelishvili, *Molecules*, 2022, **27**, 5824.
- 46 I. Papanastasiou, A. Tsotinis, G. Zoidis, N. Kolocouris, S. Radhika Prathalingam and J. M. Kelly, *ChemMedChem*, 2009, **4**, 1059–1062.
- 47 I. Papanastasiou, A. Tsotinis, N. Kolocouris, S. R. Prathalingam and J. M. Kelly, *J. Med. Chem.*, 2008, **51**, 1496–1500.

